EVE Raises AU$0.9 Million to Advance Drug Reformulation Strategy
EVE Health Group Limited (ASX: EVE) has successfully raised AU$0.9 million through a placement to sophisticated and professional investors. The capital will help propel the company’s reformulated drug programs, aimed at tapping into global markets projected to surpass US$30 billion.
EVE’s reformulation strategy focuses on improving the delivery and solubilisation of established medicines approaching patent expiry, using the company’s proprietary technologies to enhance bioavailability, onset of action, and patient convenience. The funds will support the development of reformulated drugs, including those for sexual health and cardiovascular therapies.
The company plans to use the raised capital to advance intellectual property and regulatory activities, along with progressing the delivery technologies underpinning its pipeline. The placement consists of 45.2 million shares and accompanying unlisted options, with additional options for the lead manager.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
EVE Raises AU$0.9 Million to Advance Drug Reformulation Strategy
EVE Health Group Limited (ASX: EVE) has successfully raised AU$0.9 million through a placement to sophisticated and professional investors. The capital will help propel the company’s reformulated drug programs, aimed at tapping into global markets projected to surpass US$30 billion.
EVE’s reformulation strategy focuses on improving the delivery and solubilisation of established medicines approaching patent expiry, using the company’s proprietary technologies to enhance bioavailability, onset of action, and patient convenience. The funds will support the development of reformulated drugs, including those for sexual health and cardiovascular therapies.
The company plans to use the raised capital to advance intellectual property and regulatory activities, along with progressing the delivery technologies underpinning its pipeline. The placement consists of 45.2 million shares and accompanying unlisted options, with additional options for the lead manager.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au